Literature DB >> 33485785

Patient-Reported Pain in Patients with Breast Cancer Who Receive Radiotherapy.

Bo Angela Wan1, William Pidduck1, Liying Zhang1, Amy Nolen1, Caitlin Yee1, Katie Wang1, Selina Chow1, Stephanie Chan1, Leah Drost1, Hany Soliman1, Eric Leung1, Philomena Sousa1, Donna Lewis1, Carlo DeAngelis1, Prince Taylor1, Edward Chow2.   

Abstract

BACKGROUND: Patients who receive radiation treatment (RT) for breast cancer often report pain, which contributes negatively to quality of life (QoL). AIMS: To identify demographic, treatment, and disease characteristics associated with pain and changes in pain before and after RT using the Edmonton Symptom Assessment Scale (ESAS).
DESIGN: Retrospective study. SETTINGS: Odette Cancer Centre. PARTICIPANTS: Patients diagnosed with nonmetastatic breast cancer from January 2011-June 2017 with at least one ESAS completed pre-RT and one completed post-RT.
METHODS: Data on systemic treatment, radiation, patient demographics, and disease stage were extracted. To identify factors associated with pain before and after RT and changes in pain, univariate and multivariate general linear regression analysis were conducted. p < .05 was considered statistically significant.
RESULTS: This study included 1,222 female patients with a mean age of 59 years. ESAS was completed an average of 28 days before RT (baseline) and 142 days after RT, respectively. In multivariable analysis, higher baseline pain scores were associated with having recently completed adjuvant chemotherapy (p = .002) and eventual receipt of locoregional (p = .026) or chest wall (p = .003) radiation. Adjuvant chemotherapy (p = .002) and chest wall radiation (p = .03), were associated with a significant reduction in pain score after radiotherapy, while locoregional RT was associated with a higher pain score after RT (p < .001).
CONCLUSIONS: Patients with locoregional RT had higher baseline pain that remained elevated after RT completion and should be screened for pain and provided with pain management and support when necessary.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Year:  2021        PMID: 33485785     DOI: 10.1016/j.pmn.2020.12.007

Source DB:  PubMed          Journal:  Pain Manag Nurs        ISSN: 1524-9042            Impact factor:   1.929


  2 in total

1.  Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in vitro and in vivo.

Authors:  Jing Wang; Shuting Zuo; Yan Zhang; Shanzhi Li; Ying Shi; Tonghua Du; Jicheng Han; Ningyi Jin; Yiquan Li; Xiao Li
Journal:  Cancer Manag Res       Date:  2022-09-15       Impact factor: 3.602

2.  A comparative study of the ability of recombinant oncolytic adenovirus, doxorubicin and tamoxifen to inhibit the proliferation of breast cancer cells.

Authors:  Shanzhi Li; Zhuoxin Li; Yiquan Li; Yilong Zhu; Jicheng Han; Wenjie Li; Ningyi Jin; Jinbo Fang; Xiao Li; Guangze Zhu
Journal:  J Cell Mol Med       Date:  2022-09-23       Impact factor: 5.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.